Literature DB >> 10606246

Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia.

S K Bae1, M H Bae, M Y Ahn, M J Son, Y M Lee, M K Bae, O H Lee, B C Park, K W Kim.   

Abstract

We have previously reported that the exposure of human HepG2 cells to hypoxic conditions results in the overexpression of human insulin-like growth factor II (IGF-II) mRNA whose size is 6.0 kb. This particular size of IGF-II mRNA is transcribed under the control of the IGF-II P3 promoter. In the present study, to delineate the molecular mechanism for the activation of the IGF-II gene, we examined the induction of P3 promoter activity in HepG2 cells by hypoxia in the transient expression system. In this system, hypoxia induced a linear increase within 24 h in the expression of luciferase that was driven by the IGF-II P3 promoter. To further delineate which factors mediate this response, the expression pattern of regulators of the P3 promoter, Egr-1, Sp1, and WT1, were analyzed by reverse transcription-PCR and Northern blot analysis. We found that hypoxia increased the expression of Egr-1 but not of Sp1. In contrast, the level of WT1, a repressor of IGF-II expression, was markedly decreased during hypoxia. The mRNA stability assay revealed that the induction of transcription is the mechanism of underlying Egr-1 mRNA elevation. We then investigated the effects of hypoxia on the DNA binding activity of Egr-1. Both electrophoretic mobility shift assay and supershift assay demonstrated that the DNA binding activity of the Egr-1 protein was increased by hypoxia. In addition, the level of Egr-1 protein was also increased under the hypoxia as determined by Western blot analysis. Cotransfection of HepG2 cells with an Egr-1 expression vector and an IGF-II P3 promoter-luciferase reporter plasmid showed that the transcription of IGF-II was activated by Egr-1 in a dose-dependent manner. Moreover, the elevation of IGF-II P3 promoter activity was induced synergistically by the cotreatment of hypoxia with Egr-1 overexpression. Deletion of sequences in the IGF-II P3 promoter containing Egr-1 binding sites did not respond to hypoxic stress. Taken together, these data strongly indicate that hypoxia-induced IGF-II expression in HepG2 cells is due to the enhanced activity of Egr-1 on the IGF-II P3 promoter and that the Egr-1 binding site in the IGF-II P3 promoter is essential for the transcriptional regulation of IGF-II under hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606246

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  High altitude hypoxia: an intricate interplay of oxygen responsive macroevents and micromolecules.

Authors:  S Sarkar; P K Banerjee; W Selvamurthy
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

Review 2.  Transcriptional mechanisms regulating Ca(2+) homeostasis.

Authors:  Michael F Ritchie; Yandong Zhou; Jonathan Soboloff
Journal:  Cell Calcium       Date:  2010-11-13       Impact factor: 6.817

3.  Role of promoter DNA sequence variations on the binding of EGR1 transcription factor.

Authors:  David C Mikles; Brett J Schuchardt; Vikas Bhat; Caleb B McDonald; Amjad Farooq
Journal:  Arch Biochem Biophys       Date:  2014-03-18       Impact factor: 4.013

Review 4.  Hypoxia-responsive transcription factors.

Authors:  Eoin P Cummins; Cormac T Taylor
Journal:  Pflugers Arch       Date:  2005-07-09       Impact factor: 3.657

5.  Relationship between Egr-1 gene expression and apoptosis in esophageal carcinoma and precancerous lesions.

Authors:  Ming-Yao Wu; Ying-Rui Liang; Xian-Ying Wu; Chu-Xiang Zhuang
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

6.  Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2012-08-22

7.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

8.  Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.

Authors:  Zheng Wang; You-Bing Ruan; Yang Guan; Sheng-Hong Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

9.  Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.

Authors:  Ming Yin; Xiaoxiang Guan; Zhongxin Liao; Qingyi Wei
Journal:  Am J Transl Res       Date:  2009-01-30       Impact factor: 4.060

10.  Time-dependent expression and distribution of Egr-1 during skeletal muscle wound healing in rats.

Authors:  Yan-Yan Fan; Guang-Hua Ye; Ke-Zhi Lin; Lin-Sheng Yu; Shu-Zhen Wu; Miao-Wu Dong; Jun-Ge Han; Xiang-Ping Feng; Xing-Biao Li
Journal:  J Mol Histol       Date:  2012-08-24       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.